Russell Barton
Director de Operaciones en ACUMEN PHARMACEUTICALS, INC. .
Fortuna: 309 006 $ al 30/04/2024
Cargos activos de Russell Barton
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Director de Operaciones | 01/04/2019 | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Director Técnico/Científico/I+D | 01/10/2019 | - |
| Pharma Sagacity Consulting LLC | Presidente | 01/01/2018 | - |
Historial de carrera de Russell Barton
Antiguos cargos conocidos de Russell Barton.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ELI LILLY AND COMPANY | Director de Operaciones | - | - |
Formación de Russell Barton.
| Illinois State University | Undergraduate Degree |
| Purdue University | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Empresas privadas | 2 |
|---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
| Pharma Sagacity Consulting LLC |
- Bolsa de valores
- Insiders
- Russell Barton
- Experiencia
